Department of Pharmaceutical Sciences, University of Florence, Via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy.
J Pharm Biomed Anal. 2011 Jun 25;55(4):610-7. doi: 10.1016/j.jpba.2011.01.008. Epub 2011 Jan 19.
Microemulsion formulations represent an interesting delivery vehicle for lipophilic drugs, allowing for improving their solubility and dissolution properties. This work developed effective microemulsion formulations using glyburide (a very poorly-water-soluble hypoglycaemic agent) as a model drug. First, the area of stable microemulsion (ME) formations was identified using a new approach based on mixture experiment methods. A 13-run mixture design was carried out in an experimental region defined by constraints on three components: aqueous, oil and surfactant/cosurfactant. The transmittance percentage (at 550 nm) of ME formulations (indicative of their transparency and thus of their stability) was chosen as the response variable. The results obtained using the mixture experiment approach corresponded well with those obtained using the traditional approach based on pseudo-ternary phase diagrams. However, the mixture experiment approach required far less experimental effort than the traditional approach. A subsequent 13-run mixture experiment, in the region of stable MEs, was then performed to identify the optimal formulation (i.e., having the best glyburide dissolution properties). Percent drug dissolved and dissolution efficiency were selected as the responses to be maximized. The ME formulation optimized via the mixture experiment approach consisted of 78% surfactant/cosurfacant (a mixture of Tween 20 and Transcutol, 1:1, v/v), 5% oil (Labrafac Hydro) and 17% aqueous phase (water). The stable region of MEs was identified using mixture experiment methods for the first time.
微乳液制剂是一种有前途的亲脂性药物传递载体,可提高其溶解度和溶解性能。本工作以格列吡嗪(一种水溶性很差的降血糖药物)为模型药物,开发了有效的微乳液制剂。首先,采用基于混合实验方法的新方法确定了稳定微乳液(ME)形成的区域。在由水相、油相和表面活性剂/助表面活性剂三个成分的约束所定义的实验区域内进行了 13 次运行的混合设计。微乳液制剂的透光率(在 550nm 处)(表示其透明度,因此表示其稳定性)被选为响应变量。混合实验方法得到的结果与基于伪三元相图的传统方法得到的结果非常吻合。然而,混合实验方法所需的实验工作量远远小于传统方法。然后在稳定 ME 的区域进行了随后的 13 次运行的混合实验,以确定最佳制剂(即具有最佳格列吡嗪溶解性能的制剂)。选择药物溶解百分比和溶解效率作为要最大化的响应。通过混合实验方法优化的 ME 制剂包含 78%的表面活性剂/助表面活性剂(吐温 20 和 Transcutol 的混合物,1:1,v/v),5%的油(Labrafac Hydro)和 17%的水相(水)。首次使用混合实验方法确定了 ME 的稳定区域。